Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMU3DMH)

Drug Name
ACENAPHTHOQUINONE Drug Info
Synonyms
Acenaphthenequinone; 82-86-0; Acenaphthoquinone; acenaphthylene-1,2-dione; 1,2-ACENAPHTHYLENEDIONE; Acenaphthenedione; 1,2-Acenaphthenequinone; 1,2-Acenaphthenedione; Acenaphthaquinone; Acenaphthylene-1,2-quinone; Acenaphthylenequinone; acenaphthodione; 1,2-Diketoacenaphthene; acenaphthene-1,2-dione; diketoacenaphthene; acenaphthylenedione; UNII-3950D6UEIQ; acenaphthene quinone; CCRIS 5318; CHEBI:15342; HSDB 2660; NSC 7656; EINECS 201-441-3; 1,2-dihydroacenaphthylene-1,2-dione; BRN 0879172; 3950D6UEIQ; AFPRJLBZLPBTPZ-UHFFFAOYSA-N
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
6724
ChEBI ID
CHEBI:15342
CAS Number
CAS 82-86-0
TTD Drug ID
DMU3DMH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Liver carboxylesterase (CES1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cholic Acid DM7OKQV Cholelithiasis DC11 Approved [5]
PACTIMIBE DM0NZDT Arteriosclerosis BD40 Phase 2/3 [6]
K-604 DMQVN6P Arteriosclerosis BD40 Phase 2 [7]
Eldacimibe DML7WP0 Hyperlipidaemia 5C80 Phase 2 [8]
GR148672X DM7W6YN Acute lymphoblastic leukaemia 2A85 Clinical trial [9]
Avasimibe DMFG4OM Peripheral vascular disease BD4Z Discontinued in Phase 3 [10]
E-5324 DM562BM Hyperlipidaemia 5C80 Discontinued in Phase 2 [11]
RP-64477 DMTQ3BS Hyperlipidaemia 5C80 Discontinued in Phase 2 [12]
CI-976 DMBO28J Hyperlipidaemia 5C80 Discontinued in Phase 2 [13]
CL-283796 DM7LIDT Hyperlipidaemia 5C80 Discontinued in Phase 2 [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cholinesterase (BCHE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hexafluronium bromide DMFY307 Spasm MB47.3 Approved [15]
MEPTAZINOL DMPSB8F Pain MG30-MG3Z Approved [16]
Eptastigmine DMTV7ZM Cognitive impairment 6D71 Phase 3 [17]
(-)-Phenserine DMNCY1I Alzheimer disease 8A20 Phase 3 [18]
Plasma derived human butyrylcholinesterase DMF3IBC Neurotoxicity NE61 Phase 1 [19]
Protexia DME1Y9W Alzheimer disease 8A20 Phase 1 [20]
JES-9501 DMYR3IE Alzheimer disease 8A20 Phase 1 [21]
Tetra-hydro-isoquinoline derivative 3 DMCZA45 N. A. N. A. Patented [22]
Tetra-hydro-isoquinoline derivative 1 DML86IO N. A. N. A. Patented [22]
Tetra-hydro-isoquinoline derivative 2 DM5CKVF N. A. N. A. Patented [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Prostaglandin G/H synthase 2 (PTGS2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [23]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [24]
Gamolenic acid DMQN30Z Allergy 4A80-4A85 Approved [25]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [26]
Flupentixol DM0DJ9O Schizophrenia 6A20 Approved [27]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [28]
Ibandronate DM0QZBN Hypercalcaemia 5B91.0 Approved [29]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [30]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [31]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [32]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Transcription factor p65 (RELA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [33]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [34]
Selenium DM25CGV N. A. N. A. Approved [35]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [36]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [37]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [38]
Quercetin DM3NC4M Obesity 5B81 Approved [39]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [40]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [41]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [42]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Dehydrogenase/reductase SDR family member 11 (DHRS11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [2]
Quercetin DM3NC4M Obesity 5B81 Approved [2]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [43]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [44]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [45]
Flufenamic Acid DMC8VNH Dysmenorrhea GA34.3 Approved [2]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [46]
Demecolcine DMCZQGK Solid tumour/cancer 2A00-2F9Z Approved [47]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [48]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [49]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cholinesterase (BCHE) TTEB0GD CHLE_HUMAN Inhibitor [1]
Liver carboxylesterase (CES1) TTMF541 EST1_HUMAN Inhibitor [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Dehydrogenase/reductase SDR family member 11 (DHRS11) OTU3J0ZL DHR11_HUMAN Biotransformations [2]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Gene/Protein Processing [3]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Gene/Protein Processing [4]

References

1 Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
2 Rabbit dehydrogenase/reductase SDR family member 11 (DHRS11): Its identity with acetohexamide reductase with broad substrate specificity and inhibitor sensitivity, different from human DHRS11. Chem Biol Interact. 2019 May 25;305:12-20. doi: 10.1016/j.cbi.2019.03.026. Epub 2019 Mar 26.
3 An environmental quinoid polycyclic aromatic hydrocarbon, acenaphthenequinone, modulates cyclooxygenase-2 expression through reactive oxygen species generation and nuclear factor kappa B activation in A549 cells. Toxicol Sci. 2007 Feb;95(2):348-55.
4 Activation of 5-lipoxygenase and NF-kappa B in the action of acenaphthenequinone by modulation of oxidative stress. Toxicol Sci. 2008 Jan;101(1):152-8. doi: 10.1093/toxsci/kfm252. Epub 2007 Oct 9.
5 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
6 Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and b... J Med Chem. 2008 Aug 14;51(15):4823-33.
7 A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis. 2007 Apr;191(2):290-7.
8 Prospects for drug therapy for hyperlipoproteinaemia. Diabete Metab. 1995 Apr;21(2):139-46.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2592).
10 New advances in lipid-modifying therapies for reducing cardiovascular risk. Cardiology. 2002;97(2):59-66.
11 Effect of the acyl-CoA:cholesterol acyltransferase inhibitor, E5324, on experimental atherosclerosis in rabbits. Atherosclerosis. 1994 Jun;107(2):187-201.
12 RP 64477: a potent inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase with low systemic bioavailability. Biochem Pharmacol. 1996 Feb 23;51(4):413-21.
13 Acyl-coenzyme A:cholesterol-acyltransferase (ACAT) inhibitors modulate monocyte adhesion to aortic endothelial cells. Atherosclerosis. 1995 Jan 6;112(1):7-17.
14 ACAT inhibitors CL 283,546 and CL 283,796 reduce LDL cholesterol without affecting cholesterol absorption in African green monkeys. J Lipid Res. 1995 Jun;36(6):1199-210.
15 Synergistic effect of acidosis and succinylcholine-induced hyperkalemia in spinal cord transected rats. Acta Anaesthesiol Scand. 1984 Feb;28(1):87-90.
16 Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
17 Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem. 2006 Apr 6;49(7):2174-85.
18 Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93.
19 Acetylcholinesterase-Fc Fusion Protein (AChE-Fc): A Novel Potential Organophosphate Bioscavenger with Extended Plasma Half-Life. Bioconjug Chem. 2015 Aug 19;26(8):1753-8.
20 In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact. 2005 Dec 15;157-158:363-5.
21 Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice. Eur J Pharmacol. 2001 Feb 16;413(2-3):221-5.
22 A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
23 Docosahexaenoic acid regulates gene expression in HUVEC cells treated with polycyclic aromatic hydrocarbons. Toxicol Lett. 2015 Jul 16;236(2):75-81.
24 Etoposide induces necrosis through p53-mediated antiapoptosis in human kidney proximal tubule cells. Toxicol Sci. 2015 Nov;148(1):204-19.
25 Conjugated linoleic acid, unlike other unsaturated fatty acids, strongly induces glutathione synthesis without any lipoperoxidation. Br J Nutr. 2006 Nov;96(5):811-9.
26 COX-2 and PPAR-gama confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther. 2013 Jan;12(1):69-82.
27 Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res. 1996 Sep;21(9):995-1004.
28 Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007 Dec;17(12):774-80.
29 Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res. 2006 Feb 15;66(4):2067-73.
30 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
31 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
32 A2E selectively induces cox-2 in ARPE-19 and human neural cells. Curr Eye Res. 2006 Mar;31(3):259-63.
33 Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
34 -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
35 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
36 Differential gene expression of sulindac-treated human breast epithelial cells. Int J Oncol. 2005 Dec;27(6):1727-36.
37 Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
38 Prevention of deoxycholate-induced gastric apoptosis by aspirin: roles of NF-kappaB and PKC signaling. J Surg Res. 2008 Mar;145(1):66-73. doi: 10.1016/j.jss.2007.04.039. Epub 2007 Jul 20.
39 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
40 Peroxisome proliferator-activated receptor-gamma agonists inhibit respiratory syncytial virus-induced expression of intercellular adhesion molecule-1 in human lung epithelial cells. Immunology. 2007 May;121(1):71-81. doi: 10.1111/j.1365-2567.2006.02539.x.
41 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
42 Glucosamine regulation of LPS-mediated inflammation in human bronchial epithelial cells. Eur J Pharmacol. 2010 Jun 10;635(1-3):219-26. doi: 10.1016/j.ejphar.2010.02.044. Epub 2010 Mar 20.
43 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
44 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
45 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
46 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
47 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
48 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
49 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.